← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Generx+, Inc.
Atlanta, GA
$2,472,303
Total funding
9
Grants
Funding mix
By agency
NIH$2,472,303 · 9
By mechanism
R42$1,059,627 · 2
R44$785,508 · 1
R41$429,579 · 4
R43$197,589 · 2
Investigators at Generx+, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Improved Plasmid/Liposome Administration to the Lungs$453,976
R44 · FY2002 · HL
Improved Plasmid/Liposome Administration to the Lungs$331,532
R44 · FY2003 · HL
p20, Molecular Shortstop for Inflammatory Lung Diseases$284,688
R42 · FY2003 · HL
p20, Molecular Shortstop for Inflammatory Lung Diseases$274,939
R42 · FY2002 · HL
A GENE-BASED THERAPEUTIC FOR PULMONARY HYPERTENSION$250,000
R42 · FY2000 · HL
A GENE-BASED THERAPEUTIC FOR PULMONARY HYPERTENSION$250,000
R42 · FY2001 · HL
Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis$108,690
R41 · FY2001 · DK
TGF-BETA FOR PLEURODESIS$107,000
R41 · FY2000 · HL
Single Vector Dual Gene Therapy$106,989
R41 · FY2001 · HL
P20, 'MOLECULAR SHORTSTOP'FOR INFLAMATORY LUNG DISEASES$106,900
R41 · FY2000 · HL
IMPROVED PLASMID/LIPOSOME ADMINISTRATION TO THE LUNGS$100,000
R43 · FY2000 · HL
Development of Alpha-1 Antitrypsin Gene Therapeutic as Treatment for COPD$97,589
R43 · FY2005 · HL